靶点针对疾病信息26(本栏目收费,不能显示细节,电话13136136841)
靶点针对疾病信息
INDICATI
Investigative Obesity [ICD-11: 5B80-5B81]
INDICATI
Phase 1 Sleep-wake disorder [ICD-11: 7A00-7B2Z]
INDICATI
Phase 1 Vasomotor/allergic rhinitis [ICD-11: CA08]
INDICATI
Clinical trial Insulin-resistance syndrome [ICD-11: 5A44]
INDICATI
Patented Central nervous system disease [ICD-11: 8A04-8D87]
INDICATI
Patented Eexposure to noxious substances harmful effect [ICD-11: NE61]
INDICATI
Patented General pain disorder [ICD-11: 8E43]
INDICATI
Patented Parkinsonism [ICD-11: 8A00]
INDICATI
Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z]
INDICATI
Terminated Anxiety disorder [ICD-11: 6B00-6B0Z]
INDICATI
Terminated Binge eating disorder [ICD-11: 6B82]
INDICATI
Terminated Epilepsy/seizure [ICD-11: 8A61-8A6Z]
INDICATI
Investigative Dissociative neurological symptom disorder [ICD-11: 6B60]
INDICATI
Investigative Metabolic disorder [ICD-11: 5C50-5D2Z]
TARGNAME
Histamine H3 receptor (H3R)
INDICATI
Approved Somnolence [ICD-11: MG42]